维普中文期刊产品整合服务
15篇 您的检索式:作者名="Kolitz J"
    题名 作者 年代 出处 被引量
1Leukemia:研究鉴定出与34种AML白血病亚群相关联的基因突变显示文摘针对成年急性髓细胞白血病(acute myeloid leukemia,AML)患者的一项新的大型研究将80种癌症相关基因突变与5种AML亚型相关联。这5种AML亚型可通过特异性的染色体异常加以确定。在未来,这些发现可能有助指导基因突变测试和治疗决策。A-K Eisfeld K Mrózek J Kohlschmidt D Nicolet S Orwick C J Walker K W Kroll J S Blachly A J Carroll J E Kolitz B L Powell E S Wang R M Stone A de la Chapelle J C Byrd C D Bloomfield 2017现代生物医学进展2017,17,15:7
2The immunot herapy of human cancer wit h intedeukin-2 present stat us and future directions显示文摘KOLITZ J E MERTELSMANN R 1991Cancer Invest1991,9,5:1
3A Phase Ⅱ study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse显示文摘Moore J Seiter K Kolitz J 2006Leuk Res2006,30,7:1
4A Phase Ⅱ study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse显示文摘Moore J Seiter K Kolitz J 2006Leuk Res2006,30,7:1
5Intrathoracie myeloid sarcoma 显示文摘De Corla-Souza A Kolitz J Shah R 2005J Bronchol2005,12,2:1
6Preparation of new α-hydroxy acids derived from amino acids and their corresponding polyesters显示文摘COHEN A N KATZHENDLER J KOLITZ M 2008Macromolecules2008,41,20:1
7First-in-man study of CPX-351 : a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of re- lapsed and refractory acute myeloid leukemia显示文摘FELDMAN E J LANCET JE KOLITZ JE 2011J Clin Oncol2011,29,8:1
8First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunoru bicin in a fixed 5 1 molar ratio for the treatment of relapsed and refracto-ry acute myeloid leukemia显示文摘FELDMAN E J LANCET J E KOLITZ J E 2011J Clin 0ncol2011,29,:1
9Large-scale optimization planning methods for the distribution-of United States army munitions显示文摘Clark S J Barnhart C Kolitz S E 2004Mathematical and Computer Modelling2004,39,:1
10A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse显示文摘MOORE J sErrER K KOLITZ J 2006Leuk Res2006,30,7:1
11Current therapeutic strategies for acute myeloid leukaemia显示文摘KOLITZ J E 2006Br J Haematol2006,134,6:1
12Phase I stud- y of amonafide + cytosine arabinoside (AraC) in pa- tients with poor risk acute myeloid leukemia (AML) 显示文摘Allen S L Kolitz J E Lundberg A 2005J Clin Oncol2005,2316,:1
13A Phase Ⅱstudy of Bcl-2 antisense (oblimersen sodium) combined with gerntuzumab ozo- gamicin in older patients with acute myeloid leukemia in first re- lapse显示文摘Moore J Seiter K Kolitz J 2006Leuk Res2006,30,7:1
14Evolutionary concepts for decentralized air traffic flow management 显示文摘ADAMS M KOLITZ S MILNER J 1996Air Traffic Control Quarterly1996,4,10:1
15Pharmacokineticsof CPX-351; a nano-scale liposomal fixedmolar ratio formulation of cytarabine: daunorubicin, inpatients with advanced leukemia 显示文摘FELDMAN E J KOLITZ J E TRANG J M 2012Leuk Res2012,36,10:1
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费